Dr. Shah is the founding Chief Executive Officer and President of Rocket Pharma, with a pipeline comprised of first-in-class gene therapies for rare and devasting inherited genetic diseases. Prior to this role, Gaurav was Global Program Head in the Cell & Gene Therapies Unit at Novartis, where he had strategic oversight of 12 functions and helped spearhead pivotal trials with CART-19 for patients with leukemia and lymphoma. Dr. Shah started his career in industry at ImClone/Eli Lilly as a Medical Director overseeing oncology trials focused on monoclonal antibodies. He graduated from Harvard College with a degree in behavioral neuroscience. He received his M.D. from Columbia, completed his internal medicine residency at Brigham and Women’s Hospital, and hematology/oncology fellowship training at Memorial-Sloan Kettering.